Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Antithrombin III Levels in Children with the Epidemic Form of Hemolytic-Uremic Syndrome

      , , ,

      Nephron

      S. Karger AG

      Antithrombin III, Hemolytic-uremic syndrome

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Antithrombin III (AT-III) levels were measured in 16 children suffering from the epidemic form of hemolytic-uremic syndrome (HUS) in plasma collected immediately after admission before any form of treatment. A slightly lowered concentration was found in 2 out of 16 children. Administration of AT-III concentrate as suggested in post-partum HUS is useless for the treatment of these children. Heparin infusion gives no additional risk of thrombosis because of AT-III deficiency.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1982
          1982
          03 December 2008
          : 32
          : 3
          : 261-262
          Affiliations
          University of Nijmegen, Department of Paediatrics, Nijmegen, The Netherlands
          Article
          182857 Nephron 1982;32:261–262
          10.1159/000182857
          7155244
          © 1982 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 2
          Categories
          Short Communication

          Cardiovascular Medicine, Nephrology

          Hemolytic-uremic syndrome, Antithrombin III

          Comments

          Comment on this article